Senti Biosciences Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated June 16, 2023, reports on the results of Senti Biosciences, Inc.'s virtual 2023 Annual Meeting of Stockholders. The company is incorporated in Delaware and trades on The Nasdaq Global Market under the symbol SNTI.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and stockholder voting results.
Material Changes and Voting Results
Stockholders representing 78.0% of the total shares outstanding (34,465,609 shares) participated in the meeting. The following matters were approved:
- Election of Directors: Three Class I directors were elected to serve until the 2026 annual meeting:
- Timothy Lu, M.D., Ph.D. (32,295,728 votes For)
- Edward Mathers (22,511,863 votes For)
- Omid Farokhzad, M.D. (26,184,748 votes For)
- Ratification of Auditors: KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2023 (34,350,453 votes For).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document serves solely to disclose the outcome of the stockholder vote.
Key Facts for Investor Verification
- Verify the tenure of the newly elected directors (Timothy Lu, Edward Mathers, and Omid Farokhzad) through the 2026 annual meeting.
- Confirm the appointment of KPMG LLP as the independent auditor for the fiscal year ending December 31, 2023.
- Note the high level of stockholder participation, with 78.0% of outstanding shares represented at the meeting.